Bionik Laboratories Corp.

BNKL

Bionik Laboratories Corp.

BNKL

Insider Sentiment (TTM):

Last Purchase:2023-06-09Last Sale:-Shares Purchased (TTM):0Shares Sold (TTM):0

Institutional Sentiment:

As of:N/AInstitutional Shares Owned:N/AShares Outstanding:N/AInstitutional Ownership Pct.:N/A

Earnings Market Reaction:

Filing Date:2023-06-21Price on Filing Date:N/APrevious Close:N/A% Change:N/A

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Financial Statements

10‑Q10‑K

Values in Millions ($)	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31
Assets
Assets Current
Cash And Cash Equivalents At Carrying Value	0	1	0	1	2	3	5	1	1	1	1	2	2
Accounts Receivable Net Current	0	0	1	0	0	0	0	0	0	0	1	1	1
Prepaid Expense And Other Assets Current	1	1	1	1	1	1	2	2	2	2	2	2	2
Inventory Net	1	1	1	1	1	1	1	1	1	1	1	1	1
Assets Current	3	3	3	4	5	6	7	3	3	4	5	6	6
Due From Related Parties Current	-	-	-	-	-	-	-	-	0	0	0	0	0
Property Plant And Equipment Net	0	0	0	0	0	0	0	0	0	0	0	0	0
Other Assets Noncurrent	0	0	0	-	0	-	-	-	-	-	-	-	-
Intangible Assets Net Excluding Goodwill	-	-	-	-	0	-	1	1	1	1	1	1	1
Operating Lease Right Of Use Asset	0	0	0	-	0	-	-	-	-	-	-	-	-
Finite Lived Intangible Assets Net	0	0	0	-	0	-	-	-	-	-	-	-	-
Goodwill	0	0	0	-	0	0	4	4	4	4	11	11	11
Assets	3	4	4	4	5	6	12	9	9	9	17	19	19
Liabilities And Stockhold…
Liabilities Current
Accounts Payable Current	1	0	0	0	0	0	0	1	0	1	1	0	1
Convertible Notes Payable Current	-	-	-	-	0	9	8	-	2	4	4	3	-
Accrued Liabilities Current	1	1	1	1	1	1	1	1	1	2	2	2	2
Short Term Borrowings	-	-	-	-	-	-	-	2	2	-	-	-	2
Operating Lease Liability Current	0	0	0	-	0	-	-	-	-	-	-	-	-
Contract With Customer Liability Current	0	0	0	0	0	0	0	0	0	0	1	1	0
Liabilities Current	2	2	2	2	1	10	10	4	4	7	7	7	5
Long Term Debt Noncurrent	-	-	-	-	0	0	0	2	1	-	-	-	0
Operating Lease Liability Noncurrent	0	0	0	-	0	-	-	-	-	-	-	-	-
Contract With Customer Liability Noncurrent	0	0	0	0	0	0	0	0	0	0	-	-	0
Convertible Long Term Notes Payable	2	2	1	1	0	-	-	-	-	-	-	-	-
Liabilities	5	4	3	2	2	10	10	6	6	8	-	-	5
Stockholders Equity
Preferred Stock Value	0	-	-	-	0	-	-	-	0	-	0	0	-
Common Stock Value	0	0	0	0	0	0	0	0	0	0	0	0	0
Additional Paid In Capital	99	98	98	98	98	89	89	88	88	85	85	85	85
Retained Earnings Accumulated Deficit	-100	-99	-98	-97	-95	-94	-87	-85	-85	-84	-75	-73	-71
Accumulated Other Comprehensive Income Loss Net Of…	0	0	0	0	0	0	0	0	0	0	0	0	0
Stockholders Equity	-2	-1	1	2	3	-4	2	3	3	1	10	12	13
Liabilities And Stockholders Equity	3	4	4	4	5	6	12	9	9	9	17	19	19
Special Voting Preferred Stock	0	0	0	0	0	-	-	-	0	-	-	-	-
Allowance For Doubtful Accounts Receivable Current	-	-	-	-	-	-	-	-	0	-	-	0	0
Preferred Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001
Preferred Stock Shares Authorized	5	5	5	5	5	5	5	5	5	5	10	10	10
Preferred Stock Shares Issued	0	-	-	-	0	-	-	-	0	0	-	-	0
Common Stock Par Or Stated Value Per Share	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0.001	0	0.001	0.001	0.001	0
Common Stock Shares Authorized	13	13	13	13	13	13	13	13	13	13	500	500	500
Common Stock Shares Issued	7	7	7	7	7	6	6	6	7	5	5	5	5
Shares Outstanding	-	-	-	-	-	-	-	-	-	-	5	5	5

Subscribe to unlock 17+ years of financial data, unlimited metrics, and saved tables

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, and saved tables

Start free trial

Custom Table

10‑Q10‑K

0/5

Search a metric to start building a table

Subscribe to unlock 17+ years of financial data, unlimited metrics, transformations, and saved visuals

Start 7-day free trial

Subscribe to unlock 17+ years of data, unlimited metrics, transformations, and saved visuals

Start free trial

Interactive Financial Visualizations

10‑Q10‑K

Stock Price:

OnOff

Transformations:

0/1

Search a metric to start building a visual

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Earnings Market Reaction

10‑Q10‑K

Fiscal Year	Q1 1 Month	Q1 2 Month	Q1 3 Month	Q2 1 Month	Q2 2 Month	Q2 3 Month	Q3 1 Month	Q3 2 Month	Q3 3 Month	Q4 1 Month	Q4 2 Month	Q4 3 Month
2023	-51.67%	-49.67%	-45.00%	-13.30%	107.50%	106.93%	0.00%	-35.57%	-43.62%	-18.03%	-42.62%	-57.38%
2022	-20.59%	-19.99%	17.65%	-32.50%	-60.00%	-55.00%	0.00%	-58.33%	-58.33%	0.00%	-40.00%	-71.00%
2021	-16.13%	-19.35%	-24.19%	0.67%	-17.45%	54.36%	-2.14%	-10.71%	-28.57%	-2.78%	-5.56%	-18.33%
2020	-	-	-	-	-	-	-	-	-	-7.69%	-33.33%	-33.33%
Earnings Market Reaction data beyond 3 years is for subscribers only. Unlock the full earnings market reaction history Start 7-day free trial

Subscribe to unlock 17+ years of financial data and 90+ calculated metrics

Start 7-day free trial

Subscribe to unlock 17+ years of data and 90+ calculated metrics

Start free trial

Performance and Valuation Metrics

Rows marked with a lock icon are subscribers only — subscribe to unlock 90+ calculated metrics and 17+ years of history.

Metrics	2023-03-31	2022-12-31	2022-09-30	2022-06-30	2022-03-31	2021-12-31	2021-09-30	2021-06-30	2021-03-31	2020-12-31	2020-09-30	2020-06-30	2020-03-31
Liquidity Ratios
Current Ratio	1.20	1.47	1.59	2.32	3.07	0.58	0.73	0.90	0.84	0.50	0.67	0.87	1.22
Quick Ratio	0.38	0.49	0.48	0.86	1.52	0.34	0.49	0.26	0.26	0.15	0.29	0.49	0.66
Working Capital	468.38K	983.81K	1.20M	2.23M	3.09M	-4.23M	-2.66M	-374.82K	-662.19K	-3.63M	-2.31M	-931.22K	1.04M
Leverage & Debt
Debt to Equity	-3.05	-8.06	6.32	1.51	0.60	-2.35	4.33	1.97	1.68	5.19	0.67	0.60	0.39
Interest Coverage TTM	-45.03	-16.36	-20.41	-14.49	-12.09	-13.32	-21.38	-28.16	-32.91	-77.20	-77.62	-79.48	-94.00
Debt Ratio	1.49	1.14	0.86	0.60	0.37	1.74	0.81	0.66	0.63	0.84	0.40	0.37	0.28
Efficiency & Turnover
Asset Turnover TTM	0.45	0.31	0.14	0.13	0.19	0.21	0.10	0.12	0.09	0.13	0.10	0.10	0.09
Days Sales Outstanding TTM	73.59	57.01	107.98	122.00	104.13	35.91	86.27	161.44	198.62	31.63	76.88	151.55	200.87
Receivables Turnover TTM	4.96	6.40	3.38	2.99	3.51	10.16	4.23	2.26	1.84	11.54	4.75	2.41	1.82
Per Share Metrics
Diluted EPS TTM	-0.72	-0.77	-1.63	-1.65	-1.78	-1.65	-2.00	-2.12	-2.66	-6.76	-5.59	-	-
Free Cash Flow Per Share TTM	-0.49	-0.58	-0.71	-0.68	-0.71	-0.69	-0.53	-0.63	-0.90	-0.96	-1.43	-1.90	-1.84
Dividend Per Share TTM	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Margin Metrics
Gross Profit Margin TTM	54.83%	58.07%	66.21%	68.63%	74.84%	74.81%	77.41%	78.99%	77.41%	43.33%	37.91%	41.52%	58.51%
Operating Profit Margin TTM	-267.29%	-329.64%	-961.82%	-1,247.50%	-783.00%	-617.32%	-757.22%	-758.07%	-1,117.56%	-1,259.30%	-1,057.42%	-1,121.63%	-1,165.02%
Net Profit Margin TTM	-273.99%	-354.10%	-1,015.14%	-1,341.75%	-817.14%	-630.19%	-758.90%	-750.82%	-1,141.29%	-1,270.42%	-1,059.73%	-1,348.96%	-1,515.80%
Growth Metrics
Net Revenue Growth (1Y)	41.73%	-3.22%	-28.45%	-47.40%	6.73%	-43.32%	-42.95%	-33.36%	-44.58%	1,625.29%	-	-	-
Net Income Growth (1Y)	-52.48%	-45.62%	-4.29%	-5.99%	-23.59%	-71.88%	-59.15%	-62.91%	-58.27%	146.97%	113.23%	172.96%	209.19%
EPS Growth (1Y)	-59.77%	-53.34%	-18.54%	-22.09%	-32.94%	-75.58%	-64.23%	-67.42%	-59.24%	140.25%	106.73%	101.75%	126.03%
Valuation Metrics
P/E TTM	-0.56	-0.81	-0.19	-0.61	-0.21	-0.48	-0.71	-0.85	-0.94	-0.18	-0.24	-0.30	-0.28
P/B TTM	-1.68	-8.21	3.97	4.31	0.75	-1.06	3.53	3.52	3.91	4.35	0.67	0.83	0.70
P/S TTM	1.53	2.86	1.88	8.14	1.72	3.06	5.35	6.39	10.74	2.31	2.54	4.05	4.30
Market Cap	2.76M	4.28M	2.08M	6.88M	2.19M	4.72M	8.26M	10.26M	12.82M	6.31M	6.87M	9.77M	9.27M
Enterprise Value	4.49M	5.20M	2.45M	6.05M	200.13K	10.09M	11.97M	13.63M	17.62M	9.25M	9.28M	10.82M	9.08M
Calculated Values
Free Cash Flow TTM	-3.40M	-4.02M	-4.91M	-4.70M	-4.16M	-4.07M	-3.12M	-3.61M	-4.62M	-4.94M	-7.35M	-9.53M	-9.22M
Net Debt	1.73M	916.12K	373.14K	-825.31K	-1.99M	5.37M	3.72M	3.37M	4.80M	2.95M	2.41M	1.05M	-190.91K
Per-Share and Margin
EPS TTM
Adjusted EPS TTM
Cash Flow Per Share TTM
Pretax Margin TTM
Stock Comp to Revenue TTM
Turnover Ratios and Averages
Average Assets
Average Equity
Average Inventory
Average Receivables
Average Accounts Payables
Inventory Turnover TTM
Payables Turnover TTM
Days Inventory Outstanding TTM
Days Payables Outstanding TTM
Cash Conversion Cycle TTM
Working Capital to Revenue
Deferred Revenue to Revenue
Growth Rates
Total Assets Growth (1Y)
Total Assets Growth (3Y)
Total Assets Growth (5Y)
Dividends Paid Growth (1Y)
Dividends Paid Growth (3Y)
Dividends Paid Growth (5Y)
EPS Growth (3Y)
EPS Growth (5Y)
Net Income Growth (3Y)
Net Income Growth (5Y)
Net Profit Margin Growth (1Y)
Net Profit Margin Growth (3Y)
Net Profit Margin Growth (5Y)
Net Revenue Growth (3Y)
Net Revenue Growth (5Y)
Deferred Revenue Growth (1Y)
Retained Earnings Growth (1Y)
Credit, Liquidity, Returns, Payout
Cash Ratio
Net Working Capital
Debt to EBITDA TTM
Net Debt to EBITDA TTM
Net Debt to Equity
Altman A
Altman B
Altman C
Altman D
Altman E
Altman Z-Score
ROA TTM
ROE TTM
NOPAT TTM
ROIC TTM
Effective Tax Rate TTM
Payout Ratio TTM
Dilution Ratio
Retained Earnings to Equity
Treasury Stock to Equity
Treasury Stock Change (1Y)
Accrued to Current Liabilities
NCAV
NCAV Per Share TTM
Valuation Ratios
P/CF TTM
Dividend Yield TTM
Free Cash Flow Yield TTM
EV EBITDA TTM
EV EBIT TTM
Stock Compensation TTM
Adjusted Net Income TTM
Billings TTM
Total Debt
Invested Capital

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

Insider Transactions

2023-06-09Purchase

Owner: Gaston-Dreyfus, Remi

Title: -

Shares: 180,555

Price/Share: $0.60

Value: $108,333.00

Shares Owned: 1,814,871

Relationship: Director,TenPercentOwner

Ownership: Indirect

2023-06-09Purchase

Owner: Matine, Charles

Title: -

Shares: 180,555

Price/Share: $0.60

Value: $108,333.00

Shares Owned: 206,985

Relationship: Director

Ownership: Direct

2023-06-09Purchase

Owner: Auberton-Herve, Andre-Jac…

Title: -

Shares: 650,000

Price/Share: $0.60

Value: $390,000.00

Shares Owned: 923,160

Relationship: Director

Ownership: Indirect

2021-03-29Purchase

Owner: Martin, Joseph R

Title: -

Shares: 26,430

Price/Share: -

Value: -

Shares Owned: 26,430

Relationship: Director

Ownership: Direct

2021-03-29Purchase

Owner: Matine, Charles

Title: -

Shares: 26,430

Price/Share: -

Value: -

Shares Owned: 26,430

Relationship: Director

Ownership: Direct

Filed Date	Owner	Relationship	Title	Ownership	Purchase/Sale	No. Shares	Price Per Share	Value	Shares Owned	Document Type
2023-06-09	Gaston-Dreyfus, Remi	Director,TenPercentOwner	-	Indirect	Purchase	180,555	0.60	$108,333.00	1,814,871	4
2023-06-09	Matine, Charles	Director	-	Direct	Purchase	180,555	0.60	$108,333.00	206,985	4
2023-06-09	Auberton-Herve, Andre-Jac…	Director	-	Indirect	Purchase	650,000	0.60	$390,000.00	923,160	4
2021-03-29	Martin, Joseph R	Director	-	Direct	Purchase	26,430	-	-	26,430	4
2021-03-29	Matine, Charles	Director	-	Direct	Purchase	26,430	-	-	26,430	4
2021-03-29	Thevenon, Audrey	Director	-	Direct	Purchase	26,430	-	-	26,430	4
2021-03-29	Malone, Peter Gerald	Director	-	Direct	Purchase	26,430	-	-	26,430	4
2021-03-26	Gaston-Dreyfus, Remi	Director,TenPercentOwner	-	Indirect	Purchase	135,560	-	-	1,418,194	4
2021-03-26	Auberton-Herve, Andre-Jac…	Director,Officer	Chairman	Direct	Purchase	95,149	-	-	95,149	4
Additional insider transactions are for subscribers only. Unlock the complete Form 4 filing history Start 7-day free trial

Subscribe to unlock 17+ years of financial data

Start 7-day free trial

Subscribe to unlock 17+ years of data

Start free trial

No institutional ownership data available.

Bionik Laboratories Corp. (BNKL) — SEC Financial Statements & Analysis

Bionik Laboratories Corp. (BNKL) is a orthopedic, prosthetic & surgical appliances & supplies company, incorporated in DE. Bionik Laboratories Corp. trades on OTC as: BNKL. Based on its latest SEC filing (Form 10-Q, period ending 2023-03-31), Bionik Laboratories Corp. reported a 41.73% year-over-year revenue growth, a Gross Profit Margin of 54.83% (TTM), a Debt-to-Equity ratio of -3.05x, a Price-to-Sales (P/S) ratio of 1.53x (TTM), a Price-to-Book (P/B) ratio of -1.68x (TTM), at a market cap of $2.76M. Figures below are sourced from SEC EDGAR, as-filed.

Net Revenue TTM Growth 1Y: 41.73%
Gross Profit Margin TTM: 54.83%
Debt To Equity: -3.05x
P/S TTM: 1.53x
P/B TTM: -1.68x
Market Cap: $2.76M

Data as of 2023-03-31 · Source: SEC EDGAR

Frequently Asked Questions

What industry is Bionik Laboratories Corp. in?

Bionik Laboratories Corp. (BNKL) operates in the Orthopedic, Prosthetic & Surgical Appliances & Supplies industry.

What is BNKL's market cap?

Bionik Laboratories Corp. (BNKL) has a market capitalization of $2.76M as of 2023-03-31.

What exchange does BNKL trade on?

Bionik Laboratories Corp. (BNKL) trades on the OTC.

Where is Bionik Laboratories Corp. incorporated?

Bionik Laboratories Corp. is incorporated in DE.